Paper - WANFANG MED ONLINE

You Position: Home > Paper

Progress on combination therapy for chronic hepatitis B

( views:208, downloads:104 )

Author:: No author available

Journal Title:: Chinese Journal of Clinical Infectious Diseases

Issue:: 3

DOI:: 10.3760/cma.j.issn.1674-2397.2012.03.019

Key Word:: 肝炎,乙型,慢性;抗病毒药;联合治疗;Chronic hepatitis B;Antiviral agents;Combination therapy

Abstract：慢性乙型肝炎(chronic hepatitis B,CHB)是由乙型肝炎病毒(hepatitis B virus,HBV)持续感染引起的一种严重危害人类健康的疾病,存在进展为肝硬化、肝衰竭甚至肝细胞癌的危险,是影响人类健康的一项重要问题.目前,全世界约3.5亿人感染HBV,每年有50～120万人死于HBV感染引起的肝硬化、肝衰竭,甚至原发性肝细胞癌[1-2].据统计,CHB相关肝硬化和肝细胞癌的发生率分别为30％和25％[3].CHB流行率在各地区高低不同,而我国为HBV感染高发区,一般人群的HBsAg阳性率为7.18％[4].经研究表明HBV DNA持续高水平是乙型肝炎进展的主要根源[5].抗病毒治疗可延缓疾病进展,明显提高患者的生存率,降低发生严重并发症的风险,故CHB患者的治疗目标是通过持续抑制HBV复制来延缓或逆转疾病的进展[6].

Reference

[1]耿建章,范晓红,陆海英,等.乙型肝炎肝硬化失代偿期初始拉米夫定和阿德福韦酯联合抗病毒治疗的疗效观察[J].2011,(8).
[2]马晓军,陈小苹,陈学福,等.拉米夫定与阿德福韦酯初始联合及48周时优化治疗慢性乙型肝炎[J].2012,(2).
[3]林占洲,谭斌,周华坚,等.拉米夫定联合阿德福韦酯与恩替卡韦单药治疗乙型肝炎肝硬化48周疗效对比研究[J].2011,(9).
[4]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南（2010年版）[J].2011,(1).
[5]汤雄,袁涛,陶冶.拉米夫定联合阿德福韦酯治疗HBeAg阴性慢性乙型肝炎的肝纤维化血清标记与病理评价[J].2011,(11).
[6]李兰娟,侯金林.核苷（酸）类药物联合治疗慢性乙型肝炎专家建议[J].2011,(2).
[7]Lok AS,Keeffe EB,Marrero JA,etc.Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.[J].2005,43(6).
[8]Terrault NA.Benefits and risks of combination therapy for hepatitis B.[J].2009,49(5 Suppl.).
[9]Tomlinson G,Nishikawa Y,Kowgier M,etc.Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.[J].2010,139(4).
[10]Lok AS,Oberhelman K,Husain M,etc.Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.[J].2008,48(3).
[11]Mori M,Sato K.Current and novel therapies for hepatitis B virus infection.[J].2010,10(1).
[12]Marcellin P,Boyer N,Lada O,etc.Interferon therapy for chronic hepatitis B.[J].2007,11(4).
[13]Antonucci G,Demelia L,Piccolo P,etc.A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.[J].2009,14(8).
[14]Kamar N,Lavayssiere L,Milioto O,etc.Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients.[J].2008,86(4).
[15]Sarin SK.Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.[J].2002,17(7).
[16]Perz JF,Armstrong GL,Farrington LA,etc.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.[J].2006,45(4).
[17]Vassiliadis TG,Giouleme O,Koumerkeridis.Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.[J].2010,25(1).
[18]Lok AS,McMahon BJ.Chronic hepatitis B: update 2009.[J].2009,50(3).
[19]Dienstag JL,Perrillo RP,Condreay LD,etc.Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.[J].2003,38(6).
[20]Jacobson IM,McHutchison JG,Schooley RT,etc.Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.[J].2010,105(5).
[21]Sezin Asik Akman,Sukran Kose,Oya Halicioglu.Lamivudine and adefovir resistance in children and young adults with chronic hepatitis B[J].2010,14(3).
[22]Jianhua, Yin,Hongwei, Zhang,Yongchao, He,etc.Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study.[J].2010,19(3).
[23]Lavanchy D.Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.[J].2004,11(2).
[24]Yun-Jian Sheng,Jun-Ying Liu,Shi-Wen Tong,etc.Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis[J].2011,8(1).
[25]Vlad Ratziu,Vincent Thibault,Yves BenhamouThierry Poynard.Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant[J].2006,5(1).
[26]Holoman J,Glasa J.EASL clinical practice guidelines.[J].2009,51(4).
[27]Oberhelman K,Fung SK,Conjeevaram H,etc.Virologic response and resistance to adefovir in patients with chronic hepatitis B.[J].2006,44(2).
[28]Cui, Gang,Liang, Xiaofeng,Yang, Weizhong,etc.Epidemiological serosurvey of Hepatitis B in China-Declining HBV prevalence due to Hepatitis B vaccination[J].2009,27(47).
[29]Yoo WD,Kwon HC,Cheong JY,etc.Emergence of adefovir-resistant mutants after reversion to YMDD wild-type in lamivudine-resistant patients receiving adefovir monotherapy.[J].2009,24(1).